NL-OMON45280已完成2 期
Pilot Randomized-controlled phase-IIa trial on the prevention of comorbid Depression and Obesity in Attention-deficit / Hyperactivity disorder <br> - PROUD
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt, Goethe Universität0 个研究点目标入组 55 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 64（—）
入选标准
- •- All subjects must meet DSM-5 criteria for a lifetime history of childhood onset ADHD (DSM-5 314.00, 314.01) as well as current ADHD criteria
- •- Age: 14-30 years old.
- •- Stable TAU comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of BLT or AEI).
排除标准
- •- Any severe medical or neurological condition interfering with interventions.
- •- Any severe medical or neurological condition not allowing BLT or AEI.
- •- Use of antipsychotic or anti-epileptic medication, photos-sensitising medication (e.g., Lithium, St. John's Wort)
- •- Substance use disorder (DSM-5) or dependency (DSM-5)
- •- History of epilepsy
- •- Acute suicidal ideation
- •- Pregnancy
研究者
相似试验
进行中（未招募）
1 期
A trial examining the effects of alteplase in patients with severe respiratory failure.EUCTR2010-024377-40-ATMedizinische Universität Wien, UniKlinik für Klinische Pharmakologie
进行中（未招募）
1 期
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
尚未招募
不适用
A short-term ketogenic diet combined with 24-hour fasting and chemoprotection for patients with acute myeloid leukaemiaacute myeloid leukemiaACTRN12620000850976epean Blue Mountains Local Health District134
进行中（未招募）
不适用
/ASubjects affected by non-segmental vitiligoMedDRA version: 14.1Level: PTClassification code 10062080Term: Pigmentation disorderSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000169-10-ITCLINUVEL PHARMACUETICALS LTD.60
招募中
2 期
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)Multiple myeloma2024-514527-42-00Karolinska Institutet, Karolinska Institutet62